本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Redhill Biopharma Ltd

0.7500
-0.0311-3.98%
盤後0.75000.00000.00%17:02 EDT
成交量:2.86萬
成交額:2.27萬
市值:381.92萬
市盈率:-0.12
高:0.8299
開:0.8299
低:0.7500
收:0.7811
52周最高:3.31
52周最低:0.7500
股本:509.23萬
流通股本:332.99萬
量比:1.87
換手率:0.86%
股息:- -
股息率:- -
每股收益(TTM):-6.0249
每股收益(LYR):-6.7096
淨資產收益率:-1708.61%
總資產收益率:-25.32%
市淨率:-0.87
市盈率(LYR):-0.11

資料載入中...

2026/01/22

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2026/01/22

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/12/31

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/06/30

SEC問詢函

Form CORRESP - Correspondence
2025/06/25

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/04/10

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/26

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/08/16

SEC問詢函

Form CORRESP - Correspondence
2024/06/20

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/08

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

SEC問詢函

Form CORRESP - Correspondence
2024/02/09

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2024/02/02

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/01

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/08

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/10/26

SEC問詢函

Form CORRESP - Correspondence
2023/08/10

SEC問詢函

Form CORRESP - Correspondence
2023/06/29

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/04/28

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]